Notch Therapeutics
Notch Therapeutics is a biotechnology company that develops cellular immunotherapies for cancer treatment, utilizing a proprietary platform to engineer pluripotent stem cells into therapeutic cells.
Company Overview
Notch Therapeutics develops cellular immunotherapies originating from pluripotent stem cells engineered to address complex disease systems. The company is focused on cancer treatment, specifically cell therapies providing transformational benefits compared to existing standards of care. Leveraging advanced stem cell technology, Notch Therapeutics is able to create unlimited supplies of therapeutic cells.
Proprietary T Cell-Production Platform
Notch Therapeutics boasts a proprietary T cell-production platform that integrates product design with commercially-compatible processes. This platform helps the company produce therapeutic T cells from induced pluripotent stem cells (iPSCs), enabling scalable and consistent manufacturing of cell therapies.
Office Locations
Notch Therapeutics operates offices in three key locations: Vancouver, Seattle, and Toronto. These offices facilitate the company's operations, research, and collaborations within prominent biotech and medical research hubs.
Funding and Partnerships
In February 2021, Notch Therapeutics raised $85 million in Series A financing, supporting its continued development of innovative cell therapies. The company collaborates with Allogene Therapeutics to develop iPSC-derived T cells aimed at treating hematological malignancies. It also partners with Sunnybrook Research Institute and the University of Toronto to bolster its research capabilities.